Tag Archives: favipiravir
On The Lancet editorial
On May 8, The Lancet published an editorial criticising the Narendra Modi government’s response to India’s second COVID-19 outbreak, which has been redefining the meaning of ‘snafu’. All hell broke loose. Of course, hell has been breaking loose for quite … Continue reading
Posted in Scicomm
Tagged COVID-19 epidemic, COVID-19 in India, COVID-19 pandemic, Dr Harsh Vardhan, favipiravir, hydroxychloroquine, Pankaj Chaturvedi, second wave, The Lancet, whataboutery
Comments Off on On The Lancet editorial
Spray and pray – the COVID-19 version
Kiran Mazumdar-Shaw is the head of Biocon, a company headquartered in Bengaluru and which has repurposed a drug called itolizumab – already approved to help manage severe chronic psoriasis in different markets – to manage cytokine release syndrome (CRS) in … Continue reading
Posted in Science
Tagged azithromycin, Biocon, chyavanprash, COVID-19, cytokine release syndrome, cytokine storm, favipiravir, hydroxychloroquine, Itolizumab, Kiran Mazumdar-Shaw, novel coronavirus, psoriasis, The Print
Comments Off on Spray and pray – the COVID-19 version
India’s missing research papers
If you’re looking for a quantification (although you shouldn’t) of the extent to which science is being conducted by press releases in India at the moment, consider the following list of studies. The papers for none of them have been … Continue reading
Posted in Science
Tagged Bharat Biotech, Biocon, Covaxin, COVID-19, COVID-19 epidemic, COVID-19 pandemic, ELISA test kit, favipiravir, hydroxychloroquine, Indian Council of Medical Research, Itolizumab, novel coronavirus, peer review, preprint papers, remdesivir, science academies, science by press release, seroprevalence survey, Tata Institute of Fundamental Research, tocilizumab, Zydus Cadila
Comments Off on India’s missing research papers